Cor Vasa 2004, 45(11):556-557

Asymmetrical dimethyl arginine - a new risk factor of endothelial dysfunction?

Milan Hromádka*, Jan Filipovský
II. interní klinika, Fakultní nemocnice Plzeň, Plzeň, Česká republika

Asymmetrical dimethyl arginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase, which causes endothelial dysfunction. Measurement of plasma ADMA levels can be used for risk stratification of patients with atherosclerotic disease. L-arginine supplementation might improve endothelial function in patients with elevated ADMA levels.

Keywords: Homocysteine; Asymmetrical dimethyl arginine; Atherosclerosis

Published: November 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hromádka M, Filipovský J. Asymmetrical dimethyl arginine - a new risk factor of endothelial dysfunction? Cor Vasa. 2004;45(11):556-557.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)

    • Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes